Simcere Pharmaceuticals and Idorsia announced that they have entered into a licensing agreement in China for Idorsia's daridorexant, an orexin antagonist medication used for the treatment of insomnia.
An analysis from Flinders University’s Adelaide Institute for Sleep Health looked at the potential danger of co-morbid insomnia and sleep apnea.
Results from the Wake Up America survey, conducted by The Alliance for Sleep and sponsored by Idorsia, will be presented at SLEEP 2022.
The investment will help prepare the device for volume manufacturing, develop the clinician and patient-led online platform, and achieve first sales.
JAMA Network Open has published results of SUNRISE 1 (Study 304), a pivotal Phase 3 head-to-head study that compared DAYVIGO (lemborexant), marketed by Eisai Inc, to placebo and an active comparator in patients with...
Geriatric populations are simultaneously more likely to have insomnia and less likely to tell their medical team about it.
The double whammy of co-occurring insomnia and obstructive sleep apnea (OSA) is a complex problem best managed with non-drug targeted psych interventions, an Australian study has found.